mission
Expanding human potential with remarkable technology
Paradromics is building a high-performing and durable brain-computer interface platform that opens unparalleled data access to the brain. With this advanced neurotechnology, we develop therapeutics for incurable conditions, beginning with restoring communication and autonomy for people with motor and speech disorders.
history
Signals over time
FDA Milestones
fda milestone 01
March 2023
Breakthrough Device Designation #1
Speech decoding
fda milestone 02
APRIL 2024
Breakthrough Device Designation #2
Digital device control
fda milestone 03
APRIL 2024
Total Product Life Cycle Advisory Program (TAP)
Acceptance
fda milestone 04
NOVEMBER 2025
Investigational Device Exemption (IDE)
Approval to initiate clinical study
leadership
The team reimagining what humans can do
collaborations
We are proud to advance translational research and BCI discovery alongside world-renowned institutions through the APEX Partnership Program.
University of California, Davis
University of Michigan Health
University of Pittsburgh
Stanford
University
Massachusetts General Hospital
News & Insights
Stories and developments shaping the BCI industry
Paradromics Launches APEX Partnership Program to Boost Neurotechnology Discovery
